08:56 AM EDT, 09/16/2025 (MT Newswires) -- Spectral Medical ( EDTXF ) on Tuesday said newly published findings of an observational study showed that patients with endotoxin activity, when combined with measures of organ failure, had the greatest risk of dying.

The company in a statement said prospective, multicenter observational study of 90 patients demonstrated that those with endotoxin activity (tested with Spectral's endotoxin activity assay) combined with a certain level of organ failure, had a 28-day mortality rate of 57.1%, compared with only 15.9% in other septic shock patients. This represents a more than three-fold increase in risk of death, it added.

"These findings underscore that endotoxin activity, when combined with measures of organ failure, identifies the sickest sepsis patients with the greatest likelihood of dying," said Dr. John Kellum, chief medical officer at Spectral Medial. "By precisely identifying this high-risk subgroup, we can better design clinical trials and target therapies, such as endotoxin removal, to the patients most likely to benefit."

The findings, published in Critical Care Explorations, define endotoxic septic shock (ESS) as a distinct and deadly form of septic shock. The criteria used in the study to define ESS also align with the enrollment parameters of Spectral's recently completed Tigris trial, which tested the company's PMX therapy in septic shock patients with high endotoxin levels and significant organ dysfunction.

EDT was down more than 4% on the TSX yesterday.